Document ID: chunk:federal_register_of_legislation:F2022C00585:reg:9:p2
Version: federal_register_of_legislation:F2022C00585
Segment Type: reg
Provision Reference: reg 9 (pt 2/3)
Character Range: 8188–11283

- Dictionary.
(10)      consuming a food or beverage which is associated in the individual with the following:
(a)          the development of immune thrombocytopaenia within six weeks of consuming the food or beverage; and
(b)          an absence of immune thrombocytopaenia prior to consuming the food or beverage; and
(c)          sustained recovery from immune thrombocytopaenia on ceasing consumption of the food or beverage; and
(d)          exclusion of other aetiologies for thrombocytopaenia; and
(e)          recurrence of immune thrombocytopaenia on re-exposure to the food or beverage; or
(f)           identification of platelet reactive antibodies specific to the food or beverage;
(11)      having a solid organ or stem cell transplant before the clinical onset of immune thrombocytopaenia;
(12)      having a solid organ cancer at the time of the clinical onset of immune thrombocytopaenia;
(13)      being treated with alemtuzumab in the two years before the clinical onset of immune thrombocytopaenia;
(14)      having a viral infection from the specified list of viral infections within the six weeks before the clinical worsening of immune thrombocytopaenia;
Note: specified list of viral infections is defined in the Schedule 1 - Dictionary.
(15)      having a bacterial or fungal infection from the specified list of bacterial and fungal infections, within the six weeks before the clinical worsening of immune thrombocytopaenia;
Note: specified list of bacterial and fungal  infections is defined in the Schedule 1 - Dictionary.
(16)      being treated with a drug or a drug from a class of drugs from the specified list of drugs, within the six weeks before the clinical worsening of immune thrombocytopaenia;
Note: specified list of drugs is defined in the Schedule 1 - Dictionary.
(17)      receiving a vaccine from the specified list of vaccines within the six weeks before the clinical worsening of immune thrombocytopaenia;
Note: specified list of vaccines is defined in the Schedule 1 - Dictionary.
(18)      being treated with a drug or receiving a dose of vaccine which is associated in the individual with the following:
(a)          the worsening of immune thrombocytopaenia within six weeks of drug therapy or receiving the dose of vaccine; and
(b)          recovery to the individual's baseline platelet level on ceasing drug therapy or vaccination; and
(c)          exclusion of other aetiologies for thrombocytopaenia (including other drugs or vaccines);
(19)      being pregnant within the six weeks before the clinical worsening of immune thrombocytopaenia;
(20)      having a lymphoproliferative disorder from the specified list of lymphoproliferative disorders, at the time of the clinical worsening of immune thrombocytopaenia;
Note: specified list of lymphoproliferative disorders is defined in the Schedule 1 - Dictionary.
(21)      having an autoimmune or inflammatory disorder from the specified list of autoimmune and inflammatory disorders, at the time of the clinical worsening of immune thrombocytopaenia;
Note: specified list of autoimmune and